Developments in the treatment of uveitis

Expert Opinion on Investigational Drugs

Volumn 11, Issue 1, 2002, Pages 59-67

  Kok, H ^a   Lightman, S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alpha interferon 2a; Azathioprine; Chlorambucil; Corticosteroid; Cyclosporine; Daclizumab; Etanercept; FK506; IFN alfa 2a; Immunoglobulin; Infliximab; Intravitreal drug delivery device; Leflunomide; Methotrexate; Mofetil; Monoclonal antibodies; Mycophenolate; Oral tolerance; RAPA; Rapamycin; Tacrolimus; TNF; Uveitis

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ALPHA2A INTERFERON; ANTIMETABOLITE; AZATHIOPRINE; BETAMETHASONE; CELL ADHESION MOLECULE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEFLUNOMIDE; LEUKOCYTE MIGRATION INHIBITION FACTOR; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; TEMSIROLIMUS; TERIFLUNOMIDE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR;

ACNE; BONE MARROW SUPPRESSION; CANCER; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MORBIDITY; MYALGIA; MYELODYSPLASIA; NAUSEA; OPHTHALMOLOGY; REVIEW; UVEITIS;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS, ALKYLATING; CHLORAMBUCIL; CLINICAL TRIALS; CYTOKINES; ENZYME INHIBITORS; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; T-LYMPHOCYTES; UVEITIS;

EID: 0036138903     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.1.59     Document Type: Review

References (116)

1. Causes and frequency of blindness in patients with intraocular inflammatory disease
2. Corticosteroid therapy of eye disease
3. Orbital floor steroid injection in the treatment of uveitis
4. Intravitreal injection of dexamethasone: Treatment of experimentally induced endophthalmitis
5. Intraocular management of endophthalmitis: A systemic approach
6. Effect of intravitreal dexamethasone on ocular histopathology in a rabbit model if endophthalmitis
7. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection
8. Efficacy of intravitreal dexamethasone in experimental uveitis: Effect of drug delivery in a biodegradable polymer
9. Intravitreal sustained release dexamethasone device in the treatment of experimental uveitis
10. An intravitreal device providing sustained release of cyclosporine and dexamethasone
11. Safety and pharmacokinetics of an intravitreal fluocinoloneacetonide sustained delivery device
12. Flucinolone acetonide sustained drug delivery device to treat severe uveitis
13. Safety and efficacy of introcular triamcinolone for cystoid macular oedema in uveitis
14. A controlled trial of azathioprine in Behcet's syndrome
15. Low dose methotrexate therapy in non-infectious uveitis resistant to corticosteroids
16. Low-dose methotrexate therapy for ocular inflammatory disease
17. Methotrexate treatment for sarcoid-associated panuveitis
18. Methotrexate therapy for chronic non-infectious uveitis: Analysis of a case series of 160 patients
19. Use of methotrexate in the management of sight-threatening uveitis
20. The use of methotrexate in childhood rheumatic disease
21. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R double-blind, placebo-controlled trial
22. Changing patterns in uveitis of childhood
23. RS-61443, a new potent immunosuppressive agent
24. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil
25. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism
26. Rescue therapy with mycophenolate mofetil in refractory uveitis
27. Mycophenolate mofetil: A useful immunosuppressive in inflammatory eye disease
28. Use of mycofenolate mofetil in long-term control of ocular inflammatory diseases
29. Mycophenolate mofetil
30. Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: A double-blind, randomised, multicenter trial
31. Mechanism of action for leflunomide in rheumatoid arthritis
32. Leflunomide: Inhibition of S-antigen induced autoimmune uveitis in Lewis rats
33. Cyclosporine A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents
34. Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behcet's disease
35. Immunosuppressive agents: Recent developments in molecular action and clinical application
36. Randomized double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis
37. Local cyclosporine therapy for experimental uveitis in rats
38. Intravitreal sustained-released cyclosporine in the treatment of experimental uveitis
39. Evaluation of a delivery system providing long-term release of cyclosporine
40. In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506)
41. A randomized trial of primary liver transplantation under immunosuppression with FK506 versus cyclosporine
42. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation
43. A clinical trial of FK 506 in refractory uveitis
44. FK 506 treatment of non-infectious uveitis
45. Tacrolimus (FK 506) in failed cyclosporine therapy in endogenous posterior uveitis
46. Tacrolimus (FK 506) in the treatment of posterior uveitis refractory to cyclosporine
47. The effects of FK 506 on retinal ganglion cells after optic nerve crush
48. Protective effects of FK 506 against glutamate-induced neurotoxicity in retinal cell culture
49. Topical liposomes-encapsulated FK 506 for the treatment of endotoxin-induced uveitis
50. Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction
51. Effects of steroids and immunosuppressive drugs on endotoxin-uveitis in rabbits
52. Synergistic effect of rapamycin and cyclosporine A in the treatment of experimental autoimmune uveoretinitis
53. Tacrolimus-rapamycin combination therapy for experimental autoimmune uveoretinitis
54. Treatment of Behcet's disease with chlorambucil
55. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease
56. Treatment of Behcet's disease with chlorambucil. A follow-up report
57. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease
58. Myelodysplatic syndrome with monosomy 7 after immunosuppressive therapy in Behcet's disease
59. Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative
60. Chlorambucil in Behcet's disease
61. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet disease
62. Treatment of ocular symptoms of Behcet disease with interferon 2a: A pilot study
63. Current and future trends in the use of immunosuppressive agents in patients with uveitis
64. Anti-cytokine therapy for rheumatoid arthritis
65. Etanercept in children with polyarticular juvenile rheumatoid arthritis
66. A trial of etanercept, a recombinant tumour necrosis factor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
67. Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays
68. Etanercept associated injection site reactions
69. Etanercept therapy in children with treatment resistant uveitis
70. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase 111 trial
71. Remission of Behcet's syndrome using tumour necrosis factor alpha blocking therapy
72. Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab
73. Anti-tumour necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: A case report
74. Tumour necrosis factor-alpha is not essential in endotoxin induced eye inflammation: Studies in cytokine receptor deficient mice
75. Neutralising TNF alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis
76. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab triple therapy group
77. Treatment of non-infectious intermediate and posterior uveitis with humanised antiTac mAb: A phase 1/11 clinical trial
78. Campath-1H therapy in refractory ocular inflammatory disease
79. The treatment of refractory uveitis with intravenous immunoglobulin
80. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy
81. Immunologic suppression after oral administration of antigen. Specific suppresser cells found in rat Peyer's patches after oral administration of sheep erythrocytes and their systemic migration
82. Intraocular inflammatory disease (uveitis) and the use of oral tolerence
83. Oral tolerence in a murine model of relapsing experimental auto immune uveitis (EAU): Induction of projective tolerence in primed animals
84. Treatment of uveitis by oral administration of retinal antigens: Results of a phase 1/11 randomised masked trial
85. Molecular mimicry as a therapeutic approach for an autoimmune disease: Oral treatment of uveitis patients with an MHC-peptide crossreactive with autoantigen-first results
86. Immunosuppressive therapy for chronic uveitis: Optimising therapy with steroids and cyclosporine A
87. Sirolimus rescue therapy for refractory rejection in renal transplantation
88. Sirolimus (rapamycin)-based rescue treatment following chronic rejection after liver transplantation
89. Rescue therapy: A role for sirolimus in heart and lung transplant recipients
90. Sirolimus in pediatric gastrointestinal transplantation: The use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy
91. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
92. Sirolimus: A new agent for prevention of renal allograft rejection
93. Enhanced production of in vitro tumour necrosis factor-alpha from monocytes in Behcet's disease
94. The role of tumour necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice
95. Gammadelta T-cells in behcet's disease (BD) and recurrent aphthous stomatitis (RAS)
96. Paradoxical effects of IL-10 in endotoxin-induced uveitis
97. Experimental melanin-induced uveitis in the Fisher 344 rat is inhibited by anti-CD4 monoclonal antibody, but not by mannose-6-phosphate
98. Amelioration of experimental autoimmune uveoretinitis by pretreatment with pathogenic peptide in liposome and anti-CD40 ligand monoclonal antibody
99. CD56+ T-cells in the peripheral blood of uveitis patients
100. Treatment of Behcet's disease with chlorambucil
101. Treatment of Behcet's disease with chlorambucil. A follow up report
102. The use of immunosuppressive drugs in uveitis
103. Cytokines: Their role in the uveal disease
104. Differential efficacy of tumour necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease
105. Effect of infliximab on sight-threatening panuveitis in Behcet's disease
106. Intravenous immunoglobulin therapy for resistant ocular Behcet's disease
107. Prevalence and incidence of diabetes
108. Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: Implications for tolerence therapy
109. Total dose and frequency of administration critically affect success of nasal mucosal tolerence induction
110. A humanized antibody that binds to the interleukin-2 receptor
111. Interleukin-2 receptor blockade with Daclizumab to prevent acute rejection in renal transplantation: Daclizumab triple therapy study group
112. Double-blind pilot trial of oral tolerence with myelin antigens in multiple sclerosis
113. Effects of oral administration of type 11 collagen on rheumatoid arthritis
114. Sustained-released ganciclovir therapy for treatment of cytomegalovirus retinitis: Use of an intravitreal device
115. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir